HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.